Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Is a new agent emerging for metastatic urothelial carcinoma in the 2L+ setting?
Sacituzumab tirumotecan (sac-TMT) – a next-generation TROP2-directed ADC – shows promising activity after platinum chemotherapy and immune checkpoint inhibitors.
Phase 1/2 Cohort 9 results:
- ORR: 31%
- DCR: 71%
- Median PFS: 5.5 months
- Median OS: 12.1 months
- Duration of response: Not reached
- 12-month sustained response: 53%
IHC TROP2 analysis:
- High expression: 69%
- ORR: 32%
- Low expression: 10% (Low-TROP2 sample size too small for robust response correlation)
A notable signal of antitumor activity in a heavily pretreated population.
TROP2 ADC cross-trial landscape. How does sacituzumab tirumotecan fit among other TROP2-targeted ADCs?
- Sacituzumab tirumotecan ORR: 31% Median PFS: 5.5 mo
- Sacituzumab govitecan (Phase 3) ORR: 23% No OS benefit vs chemotherapy
- Datopotamab deruxtecan ORR: ~25% Median PFS: 6.9 mo
Together, these data reinforce TROP2 as a clinically relevant therapeutic target in urothelial carcinoma. Cross-trial comparison – interpret cautiously.
Title: Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors
Authors: Y. Zhu, S. Jiang, Y. Shi, S. Wang, F. Yuan, F. Zhou, K. Jiang, X. Zhang, L. Seneviratne, G. Yu, M. Zhang, T. Liu, X. Li, X. Chen, X. Wang, S. Zhang, Y. Liu, Y. Ge, M. Chen, G. Blumenthal, O. Akala, Y. Li, X. Li, J. Ge, D. Ye
More posts on Urothelial Carcinoma.